Zomedica (ZOM) Stock May Get Attention After The Recent Sell-Off
Over the course of the year so far, the Zomedica (NYSEAMERICAN:ZOM) stock has had a rollercoaster run so far this year. At this point, the stock is trading at less than $1 a share and investors might be interested in seeing if the stock can go past that level again.
In this situation, it might be necessary for investors to take a closer look at the company and its business. The company currently boasts of one major product, the Truforma diagnostic platform for cats and dogs, which was launched in March this year. Experts believe that Zomedica, like many other penny stocks remains a speculative play; however, there are certain compelling arguments to be made regarding the stock.
It was not too long ago that the Zomedica stock was trading at $2 a share and before it can retrace its way to those levels, the company perhaps needs to ensure that it continues to grow its sales. It is sometimes possible for companies to grow if they can concentrate wholeheartedly on one thing and in case of Zomedica it is its sales.
It goes without saying that such a strategy can and often does lead to losses. However, at the same time the company is going to get the advantages that come with economies of scale.
When that happens, Zomedica will then be able to come up with other diagnostic products which will go a long way in building an entirely new ecosystem and eventually turn the company into a major player in the animal healthcare industry.
That will then turn the company from depending on the sales of its solitary product; Truforma and help in bringing about long-term growth. Zomedica has already started working on boosting its sales in a big way and recently decided to speed up the establishment of a direct sales model. These are important factors that could help the company in generating meaningful growth in the long term.
Sunshine Biopharma (SBFM) Stock Moves Toward New Highs: What’s The Plan?
There were many stocks that rallied on Tuesday but the gains in the Sunshine Biopharma (OTCMKTS:SBFM) stock was particularly notable. After the company made an announcement yesterday with regards to the working mechanisms of its anticancer product Adva-27a, the stock came into sharp focus.
As investors piled on to the Sunshine stock, it rallied strongly and ended up clocking gains of as much as 142%. The findings put forward by the company in relation to the treatment were compelling as well. Sunshine stated that Adva-27a displayed two primary activities. One was that it could evade P-glycoprotein and the other was that the treatment could inhibit Topoisomerase II.
The fact that the treatment can evade P-glycoprotein is perhaps the most important finding. It is a form of protein that is found in around 50% of all types of cancers and is responsible for resistance to treatment. There are a large number of cancer medicines that have been rendered ineffective by P-glycoprotein.
In addition to that, it is necessary to note that experts agree that resistance to a multi medicine treatment due to presence of P-glycoprotein has been regarded as one of the biggest reasons behind the failure of cancer treatments.
This feature gives Adva-27a a distinct potential competitive advantage over many of the other products in the market and hence, the rally in the stock was perhaps not such a surprise. The Chief Executive Officer of the company, Dr. Steve Silaty, spoke about the findings as well.
He said that the findings and their implications could have a considerable impact on the direction of therapies for cancer as a whole. He went on to state that the company is quite excited about the fact that Sunshine is soon going to roll out a new medicine that could have a meaningful impact on patients suffering from cancer all over the world.